Key clinical point: Patients taking biologics for inflammatory bowel disease (IBD), rheumatoid arthritis (RA) or psoriasis may have an increased risk of melanoma.

Major finding: Compared with patients taking conventional systemic therapy, patients with IBD (pRR, 1.20; 95% CI, 0.60-2.40), RA (pRR, 1.20; 95% CI, 0.83-1.74), and psoriasis (HR, 1.57; 95% CI, 0.61-4.09) had a higher but not statistically significant risk of melanoma.

Study details: An analysis of melanoma risk in 34,029 patients receiving biologics and 135,370 patients receiving conventional systemic therapy for IBD, RA, or psoriasis from seven cohort studies.

Disclosures: Mr. Esse reports being funded by a PhD studentship from the Psoriasis Association. One author disclosed receiving personal fees from Janssen, LEO Pharma, Lilly, and Novartis outside the study; another disclosed receiving grants and personal fees from those and several other pharmaceutical companies during the study, and personal fees from several pharmaceutical companies outside of the submitted work; the fourth author had no disclosures.